High extracellular matrix metalloproteinase inducer/CD147 expression is strongly and independently associated with poor prognosis in colorectal cancer

• Verfasst von: Stenzinger, Albrecht [VerfasserIn]
• Verfasst von: Goeppert, Benjamin [VerfasserIn]
• Verfasst von: Weichert, Wilko [VerfasserIn]
• Titel: High extracellular matrix metalloproteinase inducer/CD147 expression is strongly and independently associated with poor prognosis in colorectal cancer
• Verf.angabe: Albrecht Stenzinger MD, Daniel Wittschieber MD, Moritz von Winterfeld MD, Benjamin Goeppert MD, Carsten Kamphues MD, Wilko Weichert MD, Manfred Dietel MD, Anja Rabien PhD, Frederick Klauschen MD
• E-Jahr: 2012
• Jahr: 12 March 2012
• Umfang: 11 S.
• Fussnoten: Gesehen am 02.09.2020
• Titel Quelle: Enthalten in: Human pathology
• Ort Quelle: New York, NY [u.a.] : Elsevier, 1970
• Jahr Quelle: 2012
• Band/Heft Quelle: 43(2012), 9, Seite 1471-1481
• ISSN Quelle: 1532-8392
• DOI: doi:10.1016/j.humpath.2011.10.023
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Biomarker
• Sach-SW: CD147
• Sach-SW: Colorectal cancer
• Sach-SW: EMMPRIN
• Sach-SW: Prognosis
• Sach-SW: Prognosticator
• K10plus-PPN: 1572029595

Abstract

Summary. As in most solid tumors, colorectal cancer prognosis strongly depends on the extent of local invasion and lymph node and distant metastases. Extracellular matrix metalloproteinase inducer (EMMPRIN) is a transmembrane glycoprotein that activates matrix metalloproteinases, a group of enzymes that play an important role in tumor invasion and metastasis formation. This study investigates the EMMPRIN expression in a large cohort of patients with colorectal cancer. Immunohistochemical analysis of tissue microarrays from 285 patients shows that increased EMMPRIN protein expression does not correlate with clinicopathologic parameters and is an independent prognostic factor of poor survival, with mean survival times of 103 months in EMMPRIN negative/low versus 57 months in EMMPRIN intermediate/high patients (P < .001). This pronounced association of increased EMMPRIN levels and—on average—a 45% reduction in overall survival could help improve the risk stratification in patients with colorectal cancer; moreover, the lack of correlations with classical measures of cancer invasion/spreading may suggest the relevance of alternative EMMPRIN pathways beyond matrix metalloproteinase activation.